Toronto, Ontario–(Newsfile Corp. – September 23, 2021) – Microdose Psychedelic Insights is proud to announce the upcoming Psychedelic Capital: September 2021 conference to be taking place on September 30, 2021, starting at 1:30pm EDT. The September edition will engage in discussions on Novel Psychedelic Molecules and Women in Psychedelics: Exploring the role of research and therapeutic experiences. The conference will play host to a number of corporate presentations, including Entheon Biomedical (OTCQB: ENTBF)Β (FSE: 1XU1)Β and Levitee Labs (OTC Pink: LVTTF).

Click here to get a free ticket:

The virtual event will seek to provide attendees with some of the top companies, latest IPOs, newest opportunities, and deepest industry insights within the sector.

  Subscribe to news from
Entheon Biomedical

Be the first to know when breaking news are released.

Part of an investor conference series diving deep into psychedelic medicine investment, Psychedelic Capital conferences seek to introduce investors and attendees to a curated group of CEOs, capital advisors, and investment luminaries from around the world.

“Novel molecules have the potential to make psychedelic medicine more accessible and enjoyable for the average patient – not to mention, big returns for investors. But with this opportunity comes scientific uncertainty and financial risk. In [the Novel Psychedelic Molecules] panel, we’ll speak to some of the leaders in novel molecule development and learn how they navigate the promise and perils of this exciting space.” – Brom Rector, Founder, Empath Ventures/The Integration Conversation.

“The psychedelic industry exists at the crossroads between years of practical therapeutic experiences and emerging scientific research. On the Women in Psychedelics panel we’ll explore this intersection and the opportunities for women in this rapidly evolving industry. As an industry it’s important we build equitable and diverse companies by including psychedelic pioneers and welcoming new talent.” – Katie Pringle, Co-Founder & CEO of Marigold Marketing and PR.

Women in Psychedelics: Exploring the role of research and therapeutic experiences
panel features: Susan Chapelle, Kelsey Ramsden, and Katie Pringle as moderator.

”Microdose is honored to celebrate women in the psychedelics space and provide our platform to amplify diverse voices of all kinds.” – Christina Cassen, Microdose Psychedelic Insights, Chief of Staff.

The conference will seek to enable attendees to build relationships, network with professionals from across the psychedelics industry, and gain access to exciting and ground-breaking pre-IPO investment opportunities within the wider sector.

Additional information about the Psychedelic Capital: September 2021 conference, as well as details for registration, can be found here:

### Ends ###

Notes to Editors
To request media accreditation, or to arrange interviews with key personnel please contact:
Kristina Spionjak
[email protected]

About Microdose Psychedelic Insights
Microdose Psychedelic Insights aims to unlock the potential of psychedelics through Industry events, market intelligence, original, evidence-based content, strategy and community. We enable and empower society at large to make better, more mindful decisions about psychedelics and its intersection with healthcare, medicine and personal growth. We work with the industry’s most influential stakeholders, some of the world’s best-known brands and an unrivalled network of scientists, researchers, analysts, innovators, investors and advisors.

About PsyCap
This online event programming is dedicated to providing investment grade information for the nascent psychedelic sector and presents a curated group of CEOs, financial experts, thought leaders and investment luminaries from around the globe. Presentations are 30 minutes in length, with 10 minutes always allocated to a one-on-one Q&A session with the audience. Psychedelic Capital features the top companies, latest IPOs, newest opportunities and deepest insights into the emerging psychedelic space.

To view the source version of this press release, please visit